JAZZ Jazz Pharmaceuticals plc
3,935
$109.63
$3.49
(3.08%)
| Watchers | 3,935 |
| 52-Wk Low | $103.01 |
| 52-Wk High | $146.70 |
| Market Cap | $6.91B |
| Volume | 564,155.00 |
| 52-Wk High | $146.70 |
| 52-Wk Low | $103.01 |
Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst ReviewsBenzinga • 10 days ago
Latest Ratings for JAZZ
DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Mar 2022Piper SandlerMaintainsOverweight Mar 2022RBC CapitalMaintainsOutperform
View More Analyst Ratings...
Share to Feed
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference PR Newswire DUBLIN, May...
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial...
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN, April 17...
Latest Ratings for JAZZ
DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Mar 2022Piper SandlerMaintainsOverweight Mar 2022RBC CapitalMaintainsOutperform
View More Analyst Ratings...
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy...
Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen research firms that are presently covering the stock...
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Jazz Pharmaceuticals Completes Zanidatamab Biologics...
A month has gone by since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have added about 1.3% in that time frame, underperforming the S&P 500.Will the recent positive trend...
Thompson Investment Management Inc. lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ Free Report) by 24.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 6,520...